DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Atrial Myopathy and Heart Failure: Immunomolecular Mechanisms and Clinical Implications
Heart failure (HF) remains a major global health challenge defined by the inability of the heart to adequately meet systemic metabolic requirements. While ventricular dysfunction has traditionally been the primary focus in both conceptual and clinical frameworks of HF, emerging evidence highlights atrial myopathy—covering structural, functional, electrical, metabolic, and neurohormonal remodeling—as a central yet often overlooked contributor to disease progression across the HF spectrum. This review offers a comprehensive overview of the molecular and cellular mechanisms underlying atrial remodeling, with a focus on inflammation and innate immune activation as key pathogenic mediators. Among pattern recognition receptors, Toll-like receptors (TLRs) and NOD-like receptors (NLRs) play crucial roles in translating myocardial stress into pro-inflammatory, profibrotic, and pro-arrhythmic signals that exacerbate HF. By combining experimental and clinical evidence, we emphasize atrial myopathy as both a biomarker and an active driver of HF deterioration, advocating for the inclusion of atrial-targeted diagnostics and immunomodulatory therapies in future HF treatment approaches. Such a paradigm shift holds significant potential for improved risk stratification, arrhythmia prevention, attenuation of structural remodeling, and ultimately, better prognosis and clinical outcomes in this increasingly common syndrome., This work was funded by the Spanish Ministry of Science and Innovation (MICIN/AEI/10.13039/501100011033) through grants PID2023-148933OB-I00 and CNS2023-145161, and the REDINFLAMA network (grant RED2022-134511-T); by the Instituto de Salud Carlos III (ISCIII) through grants PI20/01482, PI23/01014, F21/00259, CM23/00121, CD22/00055, PMP22/00098, PT23/00028, and by CIBERCV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares). Funding was also provided by the European Regional Development Fund (ERDF), the European Social Fund (ESF), and the COMETA-Red (Consejo Superior de Investigaciones Científicas, CSIC). Additional support was provided by the Spanish Society of Cardiology—Translational Project 2019, and the Heart Rhythm Association (SEC, Spain) through the Asociación Insuficiencia Cardiaca (Trasplante Cardiaco) Project 20203. A.V.B. was supported by a Sara Borrell postdoctoral fellowship (CD22/00055), funded by the Instituto de Salud Carlos III (ISCIII), the European Union—NextGenerationEU, and the Spanish Recovery, Transformation and Resilience Plan (PRTR)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-148933OB-I00
,
AEI CNS2023-145161
,
AEI RED2022-134511-T
DOI: http://hdl.handle.net/10261/413797, https://api.elsevier.com/content/abstract/scopus_id/105015741556
HANDLE: http://hdl.handle.net/10261/413797, https://api.elsevier.com/content/abstract/scopus_id/105015741556